Genitourinary Cancers

Scott Tykodi, MD, PhD, discusses key clinical considerations that informing selection between IO/IO and IO/TKI combinations in advanced renal cell carcinoma.

Charles B. Nguyen, MD, details treatment selection in clinical practice for patients with non–clear cell renal cell carcinoma.

Subcutaneous nivolumab demonstrated comparable efficacy, safety, and tolerability to IV nivolumab in advanced clear cell renal cell carcinoma.

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.

Lor Randall, MD, FACS, on a global survey regarding enrollment criteria for a trial evaluating surgical resection for proximal femur metastases.

Clonal neoantigen load was significantly associated with promising responses to PD-1/PD-L1 and CTLA-4 combination therapy in RCC.

Laurence Albiges, MD, PhD, discusses the clinical implications of preliminary efficacy data observed with belzutifan plus lenvatinib in advanced ccRCC.

I. Alex Bowman, MD, underscores how Kidney Cancer Awareness Month enables earlier disease detection, promotes patient education, and drives vital research.

Axel Merseburger, MD, PhD, discusses AEs associated with real-world treatment discontinuations of avelumab plus axitinib in advanced renal cell carcinoma.

Alex Bowman, MD, discusses the need for early symptom recognition, genetic risk evaluation, and research support to improve RCC detection and outcomes.

Enfortumab vedotin demonstrated a manageable safety profile and no unexpected toxicities in patients aged 80 years and older with urothelial carcinoma.

Adjuvant HRQOL outcomes improved in patients with bladder cancer living in rural areas and were worse with ADT plus radiotherapy after prostatectomy.

Second-line fruquintinib plus sintilimab improved PFS, ORR, and DOR outcomes vs everolimus or axitinib monotherapy in advanced/metastatic RCC.

All the data on the tumor-agnostic approvals of T-DXd and repotrectinib are featured in this article and it's downloadable PDF visual pages!

Bradley McGregor, MD, discusses the rationale for analyzing efficacy and safety exposure response to tivozanib in patients with renal cell carcinoma.

Treatment with casdatifan was well tolerated and showed meaningful clinical activity in patients with previously treated ccRCC.

MT-8421, a novel engineered toxin body targeting CTLA-4, was not associated with grade 4 or 5 toxicities in patients with select advanced solid tumors.

Cemiplimab-based therapy is effective and has a safety profile consistent with prior reports in locally advanced/metastatic penile cancer.

Dana-Farber investigators found that normally defunct viral genes that lie dormant in the human genome can be activated in ccRCC.

Regina Barragan-Carrillo, MD, discusses findings from an analysis of global RCC clinical trial availability in high- vs low-to-middle–income countries.

Katy Beckermann, MD, PhD, discusses key findings from a PRO analysis of tivozanib/nivolumab vs tivozanib alone in ICI-pretreated RCC.

Regina Barragan-Carrillo, MD, discusses a study of RCC clinical trial availability and barriers to opening RCC clinical trials in lower-income countries.

Hedyeh Ebrahimi, MD, MPH, highlights the early activity of CBM588 plus cabozantinib/nivolumab for the treatment of patients with metastatic RCC.

Kathryn E. Beckermann, MD, PhD, details the role of tivozanib as second- and third-line therapy in patients with locally advanced or metastatic ccRCC.

Hedyeh Ebrahimi, MD, MPH, discusses clinical outcomes with CBM588 plus cabozantinib and nivolumab in metastatic renal cell carcinoma.